We are pulmonary hypertension (PH) professionals united in our vision for a world without pulmonary vascular disease (PVD). We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 Dublin - abstract deadline extended
The deadline for abstract submissions has been extended by one week – now closing on 8 October 2025, 23:59 BST. If you haven’t yet submitted or want to submit another one, this is your chance to be part of the scientific programme.
Our PVRI Digital Webinar Series alternates between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions. Don't miss out!
This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits. Find out how you can get involved.
Join us 28 January – 1 February as we celebrate 20 years of progress and innovation in PH. This year’s programme highlights advances in PAH, CTEPH, and PH in lung disease, with sessions on emerging therapies, precision medicine, and future directions.
The 'Living Legends in PH: History and Personal Perspectives' talks will feature remarkable people who have made major contributions to the field of pulmonary hypertension, bringing their science and personal stories to the worldwide PH community. Each talk will include a junior and senior facilitator to introduce the speaker and lead the discussion.
Part of the Latin America Task Force new webinar series, this session aims to evaluate PH and differential diagnosis, and the differences in phenotype presentations in Latin America and USA / Europe.
PAH is classically described as a disease in young adults, with no comorbidities. However, recent registries showed the epidemiology has changed to older patients with comorbidities (obesity, diabetes, hypertension, and coronary heart disease). In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present with a different phenotype.
Fibrotic lung diseases are often characterized by chronic inflammation and the progressive destruction of the vasculature, parenchyma, and airways, leading to cellular metabolic changes.
Our Pulmonary Hypertension Global Patient Survey (PHGPS), the largest survey to date to explore the perspectives of patients with PH at a global scale, has released initial findings from its adult cohort of 3,329 patients living with PH.
We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.
This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.
We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.
